Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Ezetimibe, a cholesterol-absorption inhibitor, reduces levels of low-density lipoprotein (LDL) cholesterol when added to statin treatment. However, the effect of ezetimibe on the progression of atherosclerosis remains unknown. METHODS: We conducted a double-blind, randomized, 24-month trial comparing the effects of daily therapy with 80 mg of simvastatin either with placebo or with 10 mg of ezetimibe in 720 patients with familial hypercholesterolemia. Patients underwent B-mode ultrasonography to assess the intima-media thickness of the walls of the carotid and femoral arteries. The primary outcome measure was the change in the mean carotid-artery intima-media thickness, which was defined as the average of the means of the far-wall intima-media thickness of the right and left common carotid arteries, carotid bulbs, and internal carotid arteries. RESULTS: The primary outcome, the mean (+/-SE) change in the carotid-artery intima-media thickness, was 0.0058+/-0.0037 mm in the simvastatin-only group and 0.0111+/-0.0038 mm in the simvastatin-plus-ezetimibe (combined-therapy) group (P=0.29). Secondary outcomes (consisting of other variables regarding the intima-media thickness of the carotid and femoral arteries) did not differ significantly between the two groups. At the end of the study, the mean (+/-SD) LDL cholesterol level was 192.7+/-60.3 mg per deciliter (4.98+/-1.56 mmol per liter) in the simvastatin group and 141.3+/-52.6 mg per deciliter (3.65+/-1.36 mmol per liter) in the combined-therapy group (a between-group difference of 16.5%, P<0.01). The differences between the two groups in reductions in levels of triglycerides and C-reactive protein were 6.6% and 25.7%, respectively, with greater reductions in the combined-therapy group (P<0.01 for both comparisons). Side-effect and safety profiles were similar in the two groups. CONCLUSIONS: In patients with familial hypercholesterolemia, combined therapy with ezetimibe and simvastatin did not result in a significant difference in changes in intima-media thickness, as compared with simvastatin alone, despite decreases in levels of LDL cholesterol and C-reactive protein. (ClinicalTrials.gov number, NCT00552097 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although the earlier ENHANCE trial could not confirm that an addition of ezetimibe to statins significantly reduces intima-media thickness in patients with familial hypercholesterolemia, the SHARP and SEAS trials highlight ezetimibe’s role in the prevention of ischaemic cardiovascular events [62–65].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [65]
In the citing paper
“the SHARP and SEAS trials highlight ezetimibe’s role in the prevention of ischaemic cardiovascular events [62–65].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [65]
Citations
Cites
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Self-citationBots, M. L., Hoes, A. W., Koudstaal, P. J., Hofman, A., & Grobbee, D. E. (1997) · Circulation · doi:10.1161/01.cir.96.5.1432 · Cited by 2,345
Self-citationNiemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
Altmann, S. W., Davis, H. R., Zhu, L.-J., Yao, X., Hoos, L. M., Tetzloff, G., Iyer, S. P. N., Maguire, M., Golovko, A., Zeng, M., et al. (2004) · Science · doi:10.1126/science.1093131 · Cited by 1,577
Pedersen, T. R. (2005) · JAMA · doi:10.1001/jama.294.19.2437 · Cited by 1,548
Self-citationBuchwald, H., Varco, R. L., Matts, J. P., Long, J. M., Fitch, L. L., Campbell, G. S., Pearce, M. B., Yellin, A. E., Edmiston, W. A., Smink, R. D., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010043231404 · Cited by 1,001
Smilde, T., van Wissen, S., Awollersheim, H., Trip, M., Kastelein, J., & Stalenhoef, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04053-8 · Cited by 918
Self-citationTaylor, A. J., Sullenberger, L. E., Lee, H. J., Lee, J. K., & Grace, K. A. (2004) · Circulation · doi:10.1161/01.cir.0000148955.19792.8d · Cited by 890
The safety of statins in clinical practice
Armitage, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60716-8 · Cited by 833
Cited by
Items 801–900 of 1,000
Pleiotropic Effects of Statins and Beyond
Lansberg, P. J. (2008) · Cardiology · doi:10.1159/000137691 · Cited by 6
Lastra, O. L. V., Méndez‐Flores, S., Cruz-Domínguez, M. P., Medina, G., Aranda, E. C., & Jara, L. J. (2016) · Lupus · doi:10.1177/0961203316631631 · Cited by 5
Clinical Update on Nursing Home Medicine: 2010
Messinger‐Rapport, B. J., Morley, J. E., Thomas, D. R., & Gammack, J. K. (2010) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2010.08.007 · Cited by 6
Transparency and Conflicts in Science: History of Influence, Scandal, and Denial
Thacker, P. D. (2020) · Accounting, finance, sustainability, governance & fraud · doi:10.1007/978-981-15-1424-1_1 · Cited by 5
Use of ezetimibe during HIV infection
Stebbing, J., Asghar, A., Holmes, P., Bower, M., Isenman, H. L., & Nelson, M. R. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn440 · Cited by 5
Novel insights on the treatment of hypercholesterolemia
Iughetti, L., Predieri, B., & Bruzzi, P. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.1033373 · Cited by 5
“Available data suggest that this combination may not restore endothelial dysfunction [7] and that ezetimibe does not influence highdensity-lipoprotein cholesterol (HDL-C), a well-known independent risk factor for cardiovascular diseases.”
BackgroundLipid lowering in patients with chronic kidney disease: a SHARP turn in the wrong direction?
Berthold, H. K., Krone, W., Erdmann, E., & Gouni‐Berthold, I. (2011) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/1741826711423116 · Cited by 5
Mascitelli, L., Ravnskov, U., Pezzetta, F., & Goldstein, M. R. (2008) · Angiology · doi:10.1177/0003319708327788 · Cited by 5
Treatment of Dyslipidemia in Elderly Patients With Coronary Heart Disease
Toth, P. P. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.06.1356 · Cited by 5
“Subsequent to publication of the ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) trial, there was a steep reduction in the prescribing of ezetimibe of two-thirds in patients on statin therapy and approximately 50% among patients not taking a statin (12).”
Long-term effects of the cholesterol level and its drug treatment
Hyttinen, L. (2011) · Cited by 5
Eficacia bioquímica y beneficio clínico de la doble inhibición con ezetimiba y simvastatina
Padial, L. R., & Soriano, F. R. (2012) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(12)70033-x · Cited by 4
All at sea: new lipid-lowering drug trials continue to disappoint
Wierzbicki, A. S. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12126 · Cited by 4
Sohn, M., Park, Y. H., & Lim, S. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0482 · Cited by 4
“Yet , the Ezetimibe and Simvastatin in Hy-percholesterolemia Enhances Atherosclerosis Regression (EN-HANCE) study [18] reported that ezetimibe’s addition to simvastatin did not mitigate atherosclerosis progression, as measured by intima-media thickness, despite superior LDL-cholesterol reduction in…”
Feeman, W. E., Williams, S. E., & Buchwald, H. (2015) · EMJ Cardiology · doi:10.33590/emjcardiol/10313436 · Cited by 4
Foex, B. A. (2009) · Anaesthesia & intensive care medicine · doi:10.1016/j.mpaic.2008.10.001 · Cited by 4
Contemporary Approaches for Evidence-Based Pharmacotherapy
Gim, S., & Vincent, W. R. (2013) · Journal of Pharmacy Practice · doi:10.1177/0897190012474232 · Cited by 4
“For example, efficacy for medications used to treat hypertension and hyperlipidemia should not be measured based on decreasing blood pressure or serum lowdensity lipoprotein, respectively, but should be gauged based on preventing clinically significant cardiovascular events.(58,59) However, surrogate outcomes are stil…”
BackgroundNiacin or Ezetimibe for Patients with, or at Risk of Coronary Heart Disease
Guthrie, R. M. (2010) · Clinical Medicine Insights Cardiology · doi:10.4137/cmc.s5970 · Cited by 4
Dislipidemia y virus de inmunodeficiencia adquirida/sida
Elías-Calles, L. C., & Calero, T. M. G. (2010) · Revista cubana de endocrinología · Cited by 4
Genetic considerations in the treatment of familial hypercholesterolemia
Moyer, A. M., & Baudhuin, L. M. (2015) · Clinical Lipidology · doi:10.2217/clp.15.33 · Cited by 4
Lipid-Lowering Strategies and Reduction of Coronary Heart Disease Risk
Hoogwerf, B. J., & Huang, J. C. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6643-9.00015-1 · Cited by 4
Sliskovic, D. R. (2013) · Wiley eBooks · doi:10.1002/9781118354483.ch5 · Cited by 4
Nguy, J., Hitchen, S. A., Lan, N. S. R., Dwivedi, G., Larbalestier, R. I., Yeap, B. B., & Fegan, P. G. (2022) · Internal Medicine Journal · doi:10.1111/imj.15700 · Cited by 4
Medical optimization of the peripheral artery disease patient
Dittman, J. M., Amendola, M. F., & Lavingia, K. S. (2022) · Seminars in Vascular Surgery · doi:10.1053/j.semvascsurg.2022.04.003 · Cited by 5
The pharmacology of cholesterol-lowering drugs: The pharmacology of cholesterol-lowering drugs
Ballantyne, C. M., & Catapano, A. L. (2022) · European Atherosclerosis Journal · doi:10.56095/eaj.v1i1.7 · Cited by 4
Pharmacists’ role in facilitating evidence-based prescribing for unlabeled use of medications
Macaulay, T. E., Cook, A. M., Fink, J. L., Rapp, R. P., & Vincent, W. R. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080352 · Cited by 4
Santos, R. D., Lorenzatti, A. J., Barros, C. F., & Escobar, E. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.02.006 · Cited by 4
Plat, A. W., Stoffers, J., de Leeuw, P. W., van Schayck, O. C. P., Soomers, F. L., Kester, A. D. M., Aretz, K., & Kroon, A. A. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283300506 · Cited by 4
Inadera, H., & Hamazaki, T. (2010) · Nippon Eiseigaku Zasshi (Japanese Journal of Hygiene) · doi:10.1265/jjh.65.506 · Cited by 4
End points in chronic heart failure clinical trials
Anand, I. S., & Florea, V. G. (2010) · Dialogues in Cardiovascular Medicine · Cited by 4
Changing characteristics of statin-related cIMT trials from 1988 to 2006
Davidson, M. H., Tomassini, J. E., Jensen, E. H., Neff, D., Polis, A. B., & Tershakovec, A. M. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.11.023 · Cited by 4
Documento Abordaje de la dislipidemia. Sociedad Española de Arteriosclerosis (parte II)
Núñez-Cortés, J. M., Alegría, E., Álvarez-Sala, J. L., Gimilio, J. A., Lahoz, C., Morató, T. M., Prieto, J. M. M., Pedro‐Botet, J., & Pintó, X. (2011) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2011.09.005 · Cited by 5
Gao, C., & Mantzoros, C. S. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00038-1 · Cited by 4
Bhattacharya, P. D., & Chaturvedi, S. (2011) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000410033.42100.db · Cited by 6
“Combination therapy reduced LDL-C by 17% and hsCRP by 26%; however, carotid intimal medial thickness was the same in both groups.(44) In the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial, clinical end points were actually measured.”
ResultThe ENHANCE trial: analysis and clinical significance
Padial, L. R. (2010) · Clinical Lipidology · doi:10.2217/clp.10.14 · Cited by 4
Waters, D. D. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.03.003 · Cited by 4
Hypercholesterolemia in Childhood
Iughetti, L., Predieri, B., & Bruzzi, P. (2015) · InTech eBooks · doi:10.5772/59760 · Cited by 5
“In fact, the combination of statin and ezetimibe may not restore endothelial dysfunction [56].”
BackgroundOmega 3 Fatty Acids Counterbalance Actions of Omega-6 Fatty Acids
Lands, B. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802844-5.00007-5 · Cited by 4
Krysiak, R. G., Szkróbka, W., & Okopień, B. (2016) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0042-113872 · Cited by 4
Paraoxonase-1 and its Interactions with HDL
Rochu, D., Chabrière, É., & Masson, P. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-382171-3.10006-3 · Cited by 8
(2009) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2009.07.0030 · Cited by 4
Assessment of new technologies: Surrogate endpoints versus outcomes, and the cost of health care
Beller, G. (2008) · Journal of Nuclear Cardiology · doi:10.1016/j.nuclcard.2008.04.004 · Cited by 4
Musunuru, K., & Blumenthal, R. S. (2008) · Clinical Cardiology · doi:10.1002/clc.20405 · Cited by 4
Letter to the Editor Atorvastatin in combination with ezetimibe and carotid atherosclerosis
Paraskevas, K. I., Mikhailidis, D. P., & Giannoukas, A. (2014) · Genetics and Molecular Research · doi:10.4238/2014.july.2.10 · Cited by 4
After ENHANCE: the cholesterol hypothesis is alive and well
Hamilton‐Craig, I. R. (2008) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2008.tb02045.x · Cited by 4
The Impact of Information Technology on the Diffusion of New Pharmaceuticals
Arrow, K. J., Bilir, K., & Sorensen, A. (2017) · National Bureau of Economic Research · doi:10.3386/w23257 · Cited by 4
Jarauta, E., Mateo‐Gállego, R., Bea, A. M., Crespo, M., Ballester, A., Rubio, M. V. R., Baila-Rueda, L., Calmarza, P., Cenarro, A., de Groot, E., et al. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.06.002 · Cited by 3
Current Ways of Treating Dyslipidemias to Prevent Atherosclerosis
Angelico, F., Baratta, F., & Ben, M. D. (2012) · Therapeutic Apheresis and Dialysis · doi:10.1111/j.1744-9987.2012.01114.x · Cited by 3
Statins and Aspirin: Do They Really Work in Women?
Desai, H. G., Hollingsworth, P. W., & Chugh, A. R. (2015) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-015-0111-x · Cited by 4
Small dense low-density lipoprotein particles: priority as a treatment target in Type 2 diabetes?
Gerber, P. A., Spinas, G. A., & Berneis, K. K. (2011) · Diabetes Management · doi:10.2217/dmt.11.73 · Cited by 3
“In a trial of carotid intima media thickness progression over 2 years in patients with familial hypercholesterinemia, it failed to show any benefit [71].”
Pharmacotherapy of Mixed Hyperlipidemia with Ezetimibe-Fenofibrate Combination Therapy
Farnier, M. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2036 · Cited by 3
The ENHANCE Study and Marketing Ezetimibe—Reply
Greenland, P. (2008) · JAMA · doi:10.1001/jama.299.23.2747-b · Cited by 3
Loewen, P. S., & Pharand, C. (2014) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.v67i3.1363 · Cited by 3
McGinnis, B., Schimmer, J. J., & Hutka, K. A. (2010) · Journal of clinical lipidology · doi:10.1016/j.jacl.2010.08.024 · Cited by 3
Kobalava, J. D., Gurevich, V. S., Galyavich, A. M., Каминный, А. И., Кашталап, В. В., Mareev, V. Y., Susekov, A. V., & Иосифович, Ш. И. (2019) · Kardiologiia · doi:10.18087/cardio.n581 · Cited by 5
Arashi, H., Yamaguchi, J., Kawada‐Watanabe, E., Otsuki, H., Sekiguchi, H., Ogawa, H., & Hagiwara, N. (2020) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248420931621 · Cited by 3
“Another author suggested that several trials have failed to demonstrate the efficacy of ezetimibe in reducing cardiovascular risk and events.(14,15) This might be due to the adverse side effects of ezetimibe; therefore, the potential of lipid-lowering therapy on serum EPA/AA ratio could not be thoroughly examined.”
BackgroundHo, H.-C., Lo, F., Lee, J., Tsai, W., & Su, T. (2023) · Pediatric Diabetes · doi:10.1155/2023/6471597 · Cited by 3
“Owing to its noninvasive nature and technological simplicity, carotid ultrasonography is widely employed in large-scale population studies to estimate future cardiovascular risk or magnitude of treatment efects [8, 9].”
Durand, A., Morgan, C. L., Tinsley, S., Hughes, E., McCormack, T., Bitchell, C. L., & Lahoz, R. (2023) · British Journal of General Practice · doi:10.3399/bjgp.2023.0010 · Cited by 4
What is the Optimum Perioperative Drug Therapy Following Lower-Extremity Vein Bypass Surgery?
Henke, P. K. (2009) · Seminars in Vascular Surgery · doi:10.1053/j.semvascsurg.2009.10.007 · Cited by 3
Regulation of Glucose Control in People with Type 2 Diabetes: A Review and Consensus
Woo, J., Park, K. S., Byun, D. W., Ko, K. S., Chung, Y., Kim, D. M., Park, T. S., Soo, B., Lee, I. K., Park, J. Y., et al. (2010) · Korean Diabetes Journal · doi:10.4093/kdj.2010.34.1.16 · Cited by 3
“Based on the results of recent studies which examined outcome results by setting specific goals for low-density lipoprotein cholesterol (ENHANCE) [12], high-density lipoprotein cholesterol (ILLUMINATE) [13], blood pressure (ONTARGET) [14], and HbA1c (ACCORD) [5] in order to prevent the occurrence of cardiovascular dis…”
ResultHypertension and Diabetes: Should We Treat Early Surrogates?
Nilsson, P. M. (2009) · Diabetes Care · doi:10.2337/dc09-s329 · Cited by 4
“FAILURES TO SHOW EFFECTS ON EARLY ATHEROSCLEROSIS — Conversely, it is known that two promising drugs for metabolic control, the lipid-lowering ezetimib and the CB1-antagonist rimonabant, failed to decrease early signs of atherosclerosis, even if LDL cholesterol and C-reactive protein were reduced by ezetimib added to…”
BackgroundInflammation of adipose tissue (Part 6). The effects of medicamental preparations
Шварц, В. Я. (2012) · Problems of Endocrinology · doi:10.14341/probl201258167-73 · Cited by 3
Yagyu, H., Nagashima, S., Takahashi, M., Miyamoto, M., Okada, K., Osuga, J.-I., & Ishibashi, S. (2012) · Endocrine Journal · doi:10.1507/endocrj.ej12-0132 · Cited by 4
Foody, J. M., & Naderi (2012) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s28159 · Cited by 3
“Therefore, despite the reduction of LDL seen with the addition of ezetimibe, these studies have yet to show further cardiovascular mortality benefit of ezetimibe in addition to a statin versus a statin alone in the general population.(20,21) The Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosi…”
Tapping, C. R., & Bratby, M. (2013) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-013-0621-3 · Cited by 3
“Adding ezetimibe (a selective cholesterol-absorption inhibitors) to the highest dose simvastatin regime has been shown to further reduce LDL and C reactive protein but did not show a decrease in carotid intima-media thickness (enhance study) [6].”
BackgroundWen, C., & Xu, H. (2011) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-011-0632-3 · Cited by 3
LDL reduction: How low should we go and is it safe?
Robinson, J. G. (2008) · Current Cardiology Reports · doi:10.1007/s11886-008-0076-3 · Cited by 5
Practice makes perfect: reflections on a primary care treatment-to-target study
Wierzbicki, A. S. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02459.x · Cited by 3
Miname, M. H., & Santos, R. D. (2013) · Clinical Lipidology · doi:10.2217/clp.13.4 · Cited by 3
Adding Ezetimibe to Statin Treatment: is LDL-C Lowering the Only benefit?
Kostapanos, M. S., Mikhailidis, D. P., & Elisaf, M. (2012) · Future Cardiology · doi:10.2217/fca.12.64 · Cited by 3
“7 percentage units, respectively) [20].”
BackgroundMethodInfluentialDoes ezetimibe modify clinical outcomes?
Turgeon, R. D., Zarnke, K. B., & Allan, G. M. (2015) · PubMed · Cited by 3
Drugs for Children with Hypercholesterolemia: Be Cautious
Iughetti, L. (2009) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2009.22.6.483 · Cited by 3
Lipid-Modifying and Antiatherosclerotic Drugs
Gotto, A. M., & Opie, L. H. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-6158-8.50015-0 · Cited by 3
Physiological and Laboratory Markers of Drug Effect
Atkinson, A. J., & Rolan, P. E. (2007) · Elsevier eBooks · doi:10.1016/b978-012369417-1/50057-2 · Cited by 3
Conroy, R., Mackie, S. A., & Boney, C. M. (2018) · Springer eBooks · doi:10.1007/978-3-319-73782-9_33 · Cited by 3
Ershova, A. I., Meshkov, A. N., Boytsov, S. A., & Балахонова, Т. В. (2011) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2011-3-113-122 · Cited by 3
“К ним относятся исследование ASAP [49] и более поздние исследования RADIANCE I (Rating Atherosclerotic Disease change by Imaging with A New CETP inhibitor 1) [27], CAPTIVATE (Carotid Atherosclerosis Progression Trial Investigating Vascular ACAT inhibition Treatment Effects) [35], ENHANCE (Ezetimibe and Simvastatin in…”
Atherosclerosis and lipoprotein metabolism
Rang, H. P., Dale, M. M., Ritter, J. M., Flower, R. J., & Henderson, G. (2012) · Elsevier eBooks · doi:10.1016/b978-0-7020-3471-8.00023-8 · Cited by 3
Combination Therapy for Dyslipidemia
Davidson, D., Wilkinson, M. J., & Davidson, M. H. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00027-x · Cited by 3
Genomics and Pharmacogenomics of Lipid-Lowering Therapies
Docherty, K. F., & Padmanabhan, S. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386882-4.00031-1 · Cited by 4
Devendra, G. P., & Krasuski, R. A. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833e4f13 · Cited by 3
History of the cholesterol hypothesis in Britain
Grimes, D. S. (2009) · QJM · doi:10.1093/qjmed/hcp029 · Cited by 3
Major Recent Trials in Cardiovascular Diseases
Artham, S. M., Lavie, C. J., & McMullan, P. W. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.03.1973 · Cited by 3
“ACCOMPLISH Avoiding Cardiovascular Events in Combination Therapy in Patients Living with Systolic Hypertension The ACCOMPLISH trial enrolled 11 400 hypertensive patients 55 years and compared fatal and nonfatal CV outcomes in patients randomized to combination treatment with the angiotensin-converting enzyme (ACE) inh…”
Statin/ezetimibe combination therapy: emerging evidence
Kalhan, A., & Rees, A. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283447835 · Cited by 3
Does 'ENHANCE' diminish confidence in ezetimibe?
Mj, G. (2008) · PubMed · Cited by 3
Managing residual risk in patients receiving statin therapy
Montgomery, B. D. (2010) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2010.tb03956.x · Cited by 3
Harrison, D. G., Brown, W. V., & Raggi, P. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.05.017 · Cited by 3
Pirillo, A., Casula, M., Baragetti, A., & Catapano, A. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15734-9.00001-7 · Cited by 3
Improving the odds: ezetimibe and cardiovascular disease
Viljoen, A., & Wierzbicki, A. S. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12613 · Cited by 2
Laufs, U. (2015) · Springer eBooks · doi:10.1007/978-3-319-20433-8_3 · Cited by 2
Tada, H., & Harada‐Shiba, M. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22041 · Cited by 2
Tratamiento combinado: pautas, indicaciones y perfil de seguridad
Muñiz-Grijalvo, O., & Ortiz, J. V. (2013) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2013.06.003 · Cited by 5
A winter’s tale: Report from the First Annual Canadian Biomarkers and Surrogate Endpoints Symposium
Heinonen, T. M., Waters, D. D., Libby, P., & Tardif, J. (2009) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(09)70143-6 · Cited by 3
“Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque.”
BackgroundSumarokov, A. B., & Kukharchuk, V. V. (2014) · Terapevticheskii arkhiv · doi:10.17116/terarkh20148612107-115 · Cited by 2
Huang, Y., Li, J., Liang, T., Zhao, Z., Xu, J., & Chen, W. (2023) · Antibiotics · doi:10.3390/antibiotics12091422 · Cited by 2
“EB is a potent inhibitor of cholesterol absorption and has been approved for the treatment of hypercholesterolemia [36,37].”
Diabetes Mellitus and Intestinal Niemann-Pick C1–Like 1 Gene Expression
Malhotra, P., Gill, R. K., Dudeja, P. K., & Alrefai, W. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801585-8.00022-1 · Cited by 5
Role of Lipoproteins in Carotid Arterial Disease
Avgerinos, E. D., & Liapis, C. D. (2013) · Springer eBooks · doi:10.1007/978-1-4471-4429-8_4 · Cited by 2
Pharmacokinetics of Lipid-Lowering Medications in Chronic Kidney Disease
Olyaei, A. J., Lassiter, J., & Lerma, E. V. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0515-7_8 · Cited by 2
“The Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE) study provides some data with regard to ezetimibe/ simvastatin combination therapy compared to simvastatin monotherapy [ 75 ].”
ResultSun, J., Liu, D., & Wang, Z. (2011) · Wiley eBooks · doi:10.1002/9781118075647.ch11 · Cited by 2
Donner‐Banzhoff, N. (2008) · Zeitschrift für Evidenz Fortbildung und Qualität im Gesundheitswesen · doi:10.1016/j.zefq.2008.07.020 · Cited by 2
Migratory polyarthritis in familial hypercholesterolemia (type IIa hyperlipoproteinemia)
Chakraborty, P. P., Mukhopadhyay, S., Achar, A., Pal, M., & Mondal, P. C. (2010) · The Indian Journal of Pediatrics · doi:10.1007/s12098-010-0021-5 · Cited by 2
Ezetimibe Use Remains Common Among Medical Inpatients
McDonald, E. G., Saleh, R., & Lee, T. C. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.10.016 · Cited by 2
“In 2008, the Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE) trial failed to demonstrate a benefit on another surrogate marker, carotid intima-media thickness, in patients with familial hypercholesterolemia.(1) Nonetheless, ezetimibe continues to be pres…”
Background
Metadata
- Authors
- Kastelein, J. J. P., Akdim, F., Stroes, E. S. G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F. H., Visseren, F. L. J., Sijbrands, E. J. G., Trip, M. D., Stein, E. A., Gaudet, D., Duivenvoorden, R., Veltri, E. P., Marais, A. D., & de Groot, E.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- University Medical Center Utrecht (NL)
- Radboud University Nijmegen (NL)
- Erasmus MC (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-04-03
- Volume
- 358
- Issue
- 14
- Pages
- 1431-1443
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2120289695
- Semantic Scholar
- 0da4a48a4d402878a4b01330a3e43a185140f586
- Cited by
- 1,241
- References
- 34
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 16 · 2023: 20 · 2022: 14 · 2021: 24 · 2020: 27 · 2019: 35 · 2018: 30 · 2017: 38 · 2016: 50 · 2015: 77 · 2014: 91 · 2013: 85 · 2012: 111
- FWCI
- 210.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- simvastatin, ezetimibe, familial hypercholesterolemia, LDL cholesterol lowering, atherosclerosis progression, carotid intima-media thickness, femoral artery, cholesterol absorption inhibition, triglycerides, C-reactive protein, statin combination therapy, lipid-lowering therapy, atherosclerotic plaque regression
- MeSH terms
- Ezetimibe, Adult, Anticholesteremic Agents, Azetidines, Carotid Arteries, Cholesterol, Double-Blind Method, Drug Therapy, Combination, Female, Femoral Artery, Humans, Hyperlipoproteinemia Type II, Cholesterol, LDL, Male, Middle Aged, Triglycerides, Ultrasonography, Treatment Outcome, Tunica Intima, Tunica Media, Simvastatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.